Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.147
Neutral
RSI(14)
49.190
Neutral
STOCH(KDJ)(9,3,3)
26.534
Neutral
ATR(14)
0.377
Low Volatility
CCI(14)
-91.629
Neutral
Williams %R
71.930
Sell
TRIX(12,20)
0.130
Sell
StochRSI(14)
75.175
Buy
Search
Puma Biotechnology Inc
PBYIAdd to Watchlist
7.930USD
+0.040+0.51%
Close 07-31 16:00（ET）Quotes delayed by 15 min
403.63MMarket Cap
16.24P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+0.51%
5 Days
-0.63%
1 Month
-4.00%
6 Months
+16.28%
Year to Date
+33.28%
1 Year
+158.31%
Key Figures
7.850Open
7.940High
264.86KVolume
16.24P/E TTM
37.83P/E Dynamic
--Dividend TTM
0.53%Turnover Ratio
7.890Prev. Close
7.630Low
1.71MTurnover
12.99P/E Static
4.05P/B
0.00%Div Yield TTM
12.54%ROA
7.89852wk High
1.12Volume Ratio
30.28MNet Profit
49.62MShares
0.4883EPS TTM
1.21Beta
21.62%ROE
3.03052wk Low
3.93%Amplitude
76.74%Gross Margin
403.63MMarket Cap
-0.97Reward/Risk
4.13%Risk Rate
TradingKey Stock Score of Puma Biotechnology Inc
Currency: USD Updated: 2026-07-31Key Insights
Puma Biotechnology Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 99 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 5.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Puma Biotechnology Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Puma Biotechnology Inc Highlights
StrengthsRisks
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 228.37M.
Overvalued
The company’s latest PE is 16.24, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 41.51M shares, decreasing 8.62% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 83.84K shares of this stock.
Analyst Rating
Based on
1
analysts
Hold
Current Rating
5.000
Target Price
-36.95%
Upside Space
Puma Biotechnology Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
1
analysts
Hold
Current Rating
5.000
Target Price
-36.95%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Puma Biotechnology Inc
PBYI
1
Amgen Inc
AMGN
38
Biogen Inc
BIIB
38
Eli Lilly and Co
LLY
35
AbbVie Inc
ABBV
32
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
7.918
Buy
MA10
8.033
Sell
MA20
8.112
Sell
MA50
7.676
Buy
MA100
7.305
Buy
MA200
6.595
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Puma Biotechnology Inc Info
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company has in-licensed and is responsible for the global development and commercialization of alisertib. It intends to pursue the development of alisertib initially in small cell lung cancer and hormone receptor positive breast cancer.
Ticker SymbolPBYI
CompanyPuma Biotechnology Inc
CEOAuerbach (Alan H)
Websitehttps://www.pumabiotechnology.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52757.700
+379.700 (+0.72%)
28474.100
+313.200 (+1.11%)
7529.900
+54.800 (+0.73%)
14613.000
-136.000 (-0.92%)
63775.000
+923.000 (+1.47%)
6400.200
+34.800 (+0.55%)
78.120
-7.814 (-9.09%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4063.160
+21.730 (+0.54%)
FAQs
What is the current price of Puma Biotechnology Inc (PBYI)?
The current price of Puma Biotechnology Inc (PBYI) is 7.93.
What is the symbol of Puma Biotechnology Inc?
The ticker symbol of Puma Biotechnology Inc is PBYI.
What is the 52-week high of Puma Biotechnology Inc?
The 52-week high of Puma Biotechnology Inc is 7.90.
What is the 52-week low of Puma Biotechnology Inc?
The 52-week low of Puma Biotechnology Inc is 3.03.
What is the market capitalization of Puma Biotechnology Inc?
The market capitalization of Puma Biotechnology Inc is 403.63M.
Is Puma Biotechnology Inc (PBYI) currently rated as Buy, Hold, or Sell?
According to analysts, Puma Biotechnology Inc (PBYI) has an overall rating of signal_hold, with a price target of 5.00.
What is the Earnings Per Share (EPS TTM) of Puma Biotechnology Inc (PBYI)?
The Earnings Per Share (EPS TTM) of Puma Biotechnology Inc (PBYI) is 0.62.